Steven Kanner
Chief Tech/Sci/R&D Officer chez CARIBOU BIOSCIENCES, INC.
Fortune : 2 M $ au 31/03/2024
Profil
Steven B.
Kanner is currently an Independent Director at Specific Biologics, Inc. since 2023 and the Chief Scientific Officer at Caribou Biosciences, Inc. since 2017.
Previously, he worked as the Vice President & Head-Biology at Arrowhead Pharmaceuticals, Inc. from 2013 to 2017.
He completed his undergraduate degree at the University of California, Berkeley and obtained doctorate degrees from the University of Miami and The University of Miami Leonard M.
Miller School of Medicine.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
20/02/2024 | 387 037 ( 0,43% ) | 2 M $ | 31/03/2024 |
Postes actifs de Steven Kanner
Sociétés | Poste | Début |
---|---|---|
CARIBOU BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 01/06/2017 |
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Director/Board Member | 10/10/2023 |
Anciens postes connus de Steven Kanner
Sociétés | Poste | Fin |
---|---|---|
ARROWHEAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/06/2017 |
Formation de Steven Kanner
University of California, Berkeley | Undergraduate Degree |
The University of Miami Leonard M. Miller School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
CARIBOU BIOSCIENCES, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Commercial Services |